Conclusion
Furthermore, the presence of residual solvents can also affect the quality and stability of pharmaceutical products. Solvents may interact with active pharmaceutical ingredients (APIs), potentially altering their efficacy or leading to degradation over time. This is particularly critical in the development of pharmaceuticals intended for chronic conditions, where long-term efficacy and safety are paramount. Thus, manufacturers must conduct thorough risk assessments and implement appropriate control measures to minimize solvent levels and their associated risks.